Motley Fool14d agoneutral
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
76last 24h
977last 7d
110● bullish (7d)
126● bearish (7d)
212publishers
Quartz22d agoneutral
Nvidia pauses AI cloud revenue-sharing deals over antitrust concernsThe chip giant stepped back from the AI Compute Partnership program last week, less than two months after announcing it in July